Canada House announces its first Toronto clinic in North York’s Champagne Centre to extend its reach to new patients
February 21 2019 - 6:00AM
Canada House Wellness Group Inc. (“Canada House” or the “Company”)
(CSE:CHV) is pleased to announce the opening of its first Toronto
clinic this Spring at the Champagne Centre, a multidisciplinary
medical complex in North York. As a pioneer in cannabinoid therapy
clinics, Canada House Clinics (CHC) is expanding to larger centres
due to a significant and growing demand amongst key demographics
including Boomers and Seniors, in addition to the Veterans
historically serviced by its clinics.
“Building on our special relationship with Veterans, Canada
House is helping all Canadians who are serious about using medical
cannabis to improve their health and well-being,” says Chris
Churchill-Smith, CEO. “The Champagne Centre is ideal due to the
large number of patients using the facility on a daily basis.
We are extremely excited to have secured a lease there for our
first Toronto clinic as we look to execute on Clinic expansion
plans targeting larger urban centres throughout Canada.”
The Champagne Centre is an innovative 270,000 square foot
health, sports, and wellness complex that includes the PolyClinic
Family and Specialty Medicine Facility which has over 70 physicians
and a wide range of diagnostic testing facilities. The strategic
location will assist Canada House in extending its reach to new
patients with specific health and wellness concerns. In addition, a
major hospital in North York recently announced its plans to open a
large outpatient clinic in the Champagne Centre in 2019, adding to
the 1,200 patients per day that visit the Champagne Centre.
“The philosophy of the Champagne Centre to create a quality
health village with all specialties and services in one location
resonates with the medical mission of Canada House Clinics,” says
Alex Kroon, President Canada House Clinics. “We look forward to
working with referring doctors in the Champagne Centre and across
Toronto.”
Canada House is committed to working with the health system to
secure coverage for medical cannabis patients by taking an
evidence-based medical approach to responsible and effective
cannabinoid therapy. CHC’s first Toronto clinic is yet another step
in this direction, endeavoring to reach out to potential new users
of medical cannabis.
For further information, please contact:
Boom Capital Markets Steve Low 647-620-5101
steve@boomcapitalmarkets.com
Canada House Wellness Group Inc. Chris Churchill-Smith, CEO
514-313-0102 chris.smith@canadahouse.ca
___________________________________________________________________________
ABOUT CANADA HOUSE WELLNESS GROUP INC. Canada
House is an experienced, integrated medical cannabis company
providing patient-specific cannabinoid therapy products and
services through its clinics and licensed producer. Canada House is
the parent company of Canada House Clinics Inc., Knalysis
Technologies and Abba Medix Corp. For more information, please
visit www.canadahouse.ca or www.sedar.com.
Cautionary Statement Regarding Forward Looking Information. This
press release contains forward-looking statements, including
statements that relate to, among other things, the Company’s
clinic, production and technology businesses, its future plans, the
Company’s markets, objectives, goals, strategies, intentions,
beliefs, expectations and estimates, and can generally be
identified by the use of words such as “may”, “will”, “could”,
“should”, “would”, “likely”, “possible”, “expect”, “intend”,
“estimate”, “anticipate”, “believe”, “plan”, “objective” and
“continue” (or the negative thereof) and words and expressions of
similar import. Although the Company believes that the expectations
reflected in such forward-looking statements are reasonable, such
statements involve risks and uncertainties, and undue reliance
should not be placed on such statements.
Certain material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Material assumptions used to develop forward-looking information in
this news release include, among other things, the regulations
related to cannabis use under the Access to Cannabis for Medical
Purposes Regulations and the act respecting cannabis and to amend
the Controlled Drugs and Substances Act, the Criminal Code and
other Acts, passed by the Canadian Federal government, making
cannabis legal for recreational use by October 17, 2018; Company
liquidity and capital resources, including the availability of
additional capital resources to fund its activities; level of
competition; the ability to adapt products and services to the
changing market; the ability to attract and retain key executives;
and the ability to execute strategic plans. Additional information
about material factors that could cause actual results to differ
materially from expectations and about material factors or
assumptions applied in making forward-looking statements may be
found in the Company’s most recent annual and interim Management’s
Discussion and Analysis under “Risk and Uncertainties” as well as
in other public disclosure documents filed with Canadian securities
regulatory authorities. The Company does not undertake any
obligation to update publicly or to revise any of the
forward-looking statements contained in this document, whether as a
result of new information, future events or otherwise, except as
required by law.
Neither the CSE nor its Regulation Services Provider (as that
term is defined in the policies of the CSE) accepts responsibility
for the adequacy or accuracy of this release.
Churchill Ventures Ltd (AMEX:CHV)
Historical Stock Chart
From May 2024 to Jun 2024
Churchill Ventures Ltd (AMEX:CHV)
Historical Stock Chart
From Jun 2023 to Jun 2024